Michael J. Overman, MD, on Colorectal Cancer: Updated Results From CheckMate 142

2017 Gastrointestinal Cancers Symposium
Tweet this page

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).

Advertisement

Advertisement



Advertisement

click me